Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
This leaflet is part III of a three-part “Product Monograph" published when MYLAN-GABAPENTIN was approved for sale in Canada and is designed specifically for Consumers. This leaflet is part III of a three-part “Product Monograph" published when NEURONTIN was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about NEURONTIN. Contact your doctor or pharmacist if you have any questions about the drug. This leaflet is part III of a three-part "Product Monograph" published when GABAPENTIN was approved for sale in Canada and is designed specifically for Consumers. This leaflet is part III of a three-part “Product Monograph" published when TEVA-GABAPENTIN was approved for sale in Canada and is designed specifically for Consumers. NEURONTIN may cause you to feel dizzy or drowsy. Avoid driving, using machinery, or doing dangerous activities until you know how NEURONTIN affects you. Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines. PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrNEURONTIN® Gabapentin Capsules Capsules, 100 mg, 300 mg and 400 mg, oral Drug and Health Product Portal Information on drugs and health products authorized by Health Canada. This leaflet is part III of a three-part “Product Monograph" published when Neurontin was approved for sale in Canada and is designed specifically for Consumers. This leaflet is part III of a three-part “Product Monograph" published when NEURONTIN was approved for sale in Canada and is designed specifically for Consumers. A double-blind, randomized, two-way crossover, single-dose (1 x 400 mg) bioequivalence study of GABAPENTIN 400 mg capsules (Teva Canada Limited) and NEURONTIN® 400 mg capsules (Upjohn EESV) was conducted in 38 healthy adult male subjects under fasting conditions. NEURONTIN® (gabapentin) Product Monograph management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice. Consumer Information Information about the product including what the product is used for, dosage, warnings, proper use and side effects. This summary will not tell you everything about the product. Contact your healthcare professional if you have any questions about the product. The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the Gabapentin (Neurontin®) Why is this medication prescribed? • To treat pain from damaged nerves (neuropathic pain). Gabapentin works by dampening the pain signals sent through the body’s nervous system. • Gabapentin can also be used in the treatment of seizure disorders. How should this medication be used? 1 NEURONTIN® (Gabapentin Capsules, 100 mg, 300 mg and 400 mg; Gabapentin Tablets, 600 mg and 800 mg), submission control 275525, Product Monograph, BGP Pharma ULC. PRODUCT MONOGRAPH Pr NEURONTIN® Gabapentin Capsules 100 mg, 300 mg, and 400 mg Tablets 600 mg and 800 mg Antiepileptic Agent Pfizer Canada ULC Date of Revision: 17,300 Trans-Canada Highway January 27, 2020 Kirkland, Quebec H9J 2M5 www.pfizer.ca Submission Control No: 232770 ®TM Warner-Lambert Company LLC Pfizer Canada ULC, Licensee ©Pfizer Canada ULC 2019 NEURONTIN® (gabapentin) Product IMPORTANT: PLEASE READ: This leaflet is part III of a three-part “Product Monograph” published when NEURONTIN was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about NEURONTIN. Contact your doctor or pharmacist if you have any questions about the drug. *RIVA-GABAPENTIN (gabapentin) 600 mg tablets; manufactured by Shasun Pharmaceuticals Ltd., India for Laboratoire Riva Inc., Blainville, Québec, Canada †NEURONTIN® (gabapentin) 600 mg tablets (Pfizer Canada Inc.; previously Parke-Davis, Division of Warner-Lambert Canada Inc.), were purchased in Canada § Expressed as the median value (range Product Details Neurontin ODB Formulary Therapeutic Classification 28:12:00 Anticonvulsants Therapeutic Note NO ATC Code N02BF01 Interchangeable Products LU Clinical Criteria NO EAP Criteria NO Product Monograph View Monograph Drug and Health Product Portal Information on drugs and health products authorized by Health Canada.
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |